Adjuvants for Enhancing the Immunogenicity of Whole Tumor Cell Vaccines

REFERENCES

• Zajac AJ, Blattman JN, Murali-Krishna K, Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 1998;188:2205–2213.
   PubMed Web of Science ®Google Scholar
• Neller MA, López JA, Schmidt CW. Antigens for cancer immunotherapy. Semin Immunol 2008;20:286–295.
   PubMed Web of Science ®Google Scholar
• Sauter B, Albert ML, Francisco L, Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000;191:423–434.
   PubMed Web of Science ®Google Scholar
• Somersan S, Larsson M, Fonteneau JF, Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. J Immunol 2001;167:4844–4852.
   PubMed Web of Science ®Google Scholar
• Asea A, Kraeft S-K, Kurt-Jones EA, HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 2000;6:435–442.
   PubMed Web of Science ®Google Scholar
• Wang X-Y, Arnouk H, Chen X, Extracellular targeting of endoplasmic reticulum chaperone glucose-regulated protein 170 enhances tumor immunity to a poorly immunogenic melanoma. J Immunol 2006;177:1543–1551.
   PubMed Web of Science ®Google Scholar
• Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418:191–195.
   PubMed Web of Science ®Google Scholar
• Wang H, Bloom O, Zhang M, HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248–251.
   PubMed Web of Science ®Google Scholar
• Apetoh L, Ghiringhelli F, Tesniere A, Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13:1050–1059.
   PubMed Web of Science ®Google Scholar
• Hu D-E, Moore AM, Thomsen LL, Brindle KM. Uric acid promotes tumor immune rejection. Cancer Res 2004;64:5059–5062.
   PubMed Web of Science ®Google Scholar
• Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003;425:516–521.
   PubMed Web of Science ®Google Scholar
• Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol 1997;15:821–850.
   PubMed Web of Science ®Google Scholar
• Li M, Davey GM, Sutherland RM, Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J Immunol 2001;166:6099–6103.
   PubMed Web of Science ®Google Scholar
• Lopez MN, Pereda C, Segal G, Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed Type IV hypersensitivity response and reduction of tumor growth factor (beta)-expressing T cells. J Clin Oncol 2009;27:945–952.
   PubMed Web of Science ®Google Scholar
• Hernando J, Park T, Kübler K, Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: Clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother 2002;51:45–52.
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Menard C, Puig P, Metronomic cyclophosphamide regimen selectively depletes CD4 & CD25 regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56:641–648.
   PubMed Web of Science ®Google Scholar
• Kandalaft LE, Facciabene A, Buckanovich RJ, Coukos G. Endothelin B receptor, a new target in cancer immune therapy. Clin Cancer Res 2009;15:4521–4528.
   PubMed Web of Science ®Google Scholar
• Fadok VA, Bratton DL, Rose DM, A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature 2000;405:85–90.
   PubMed Web of Science ®Google Scholar
• Larsson M, Fonteneau JF, Bhardwaj N. Dendritic cells resurrect antigens from dead cells. Trends Immunol 2001;22:141–148.
   PubMed Web of Science ®Google Scholar
• Jenne L, Arrighi J-F, Jonuleit H, Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis. Cancer Res 2000;60:4446–4452.
   PubMed Web of Science ®Google Scholar
• Obeid M, Tesniere A, Ghiringhelli F, Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007;13:54–61.
   PubMed Web of Science ®Google Scholar
• Obeid M, Panaretakis T, Joza N, Calreticulin exposure is required for the immunogenicity of [gamma]-irradiation and UVC light-induced apoptosis. Cell Death Differ 2007;14:1848–1850.
   PubMed Web of Science ®Google Scholar
• Tian J, Avalos AM, Mao S-Y, Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007;8:487–496.
   PubMed Web of Science ®Google Scholar
• Bell CW, Jiang W, Reich CF, III, Pisetsky DS. The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 2006;291:C1318–C1325.
   PubMed Web of Science ®Google Scholar
• Rovere P, Peri G, Fazzini F, The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. Blood 2000;96:4300–4306.
   PubMed Web of Science ®Google Scholar
• Baruah P, Propato A, Dumitriu IE, The pattern recognition receptor PTX3 is recruited at the synapse between dying and dendritic cells, and edits the cross-presentation of self, viral, and tumor antigens. Blood 2006;107:151–158.
   PubMed Web of Science ®Google Scholar
• Benencia F, Courreges M, Coukos G. Whole tumor antigen vaccination using dendritic cells: Comparison of RNA electroporation and pulsing with UV-irradiated tumor cells. J Transl Med 2008;6:21–34.
   PubMed Web of Science ®Google Scholar
• Courreges MC, Benencia F, Conejo-Garcia JR, Preparation of apoptotic tumor cells with replication-incompetent HSV augments the efficacy of dendritic cell vaccines. Cancer Gene Ther 2005;13:182–193.
   Google Scholar
• Schlienger K, Chu CS, Woo EY, TRANCE- and CD40 Ligand-matured dendritic cells reveal MHC Class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res 2003;9:1517–1527.
   PubMed Web of Science ®Google Scholar
• Baars A, Claessen AME, Van Den Eertwegh AJM, Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: Experience in 81 patients. Ann Oncol 2000;11:965–970.
   PubMedGoogle Scholar
• Hodi FS, Butler M, Oble DA, Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 2008;105:3005–3010.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Mihm MC, Soiffer RJ, Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003;100:4712–4717.
   PubMed Web of Science ®Google Scholar
• Dillman RO, DePriest C, DeLeon C, Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: Results of exploratory phase I/II trials in patients with metastatic melanoma. Cancer Biother Radiopharm 2007;22:309–321.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Nanci AA, Williams ST, Durable complete response of refractory, progressing metastatic melanoma after treatment with a patient-specific vaccine. Cancer Biother Radiopharm 2010;25:553–557.
   PubMed Web of Science ®Google Scholar
• Allison MED, Fearon DT. Enhanced immunogenicity of aldehyde-bearing antigens: A possible link between innate and adaptive immunity. Eur J Immunol 2000;30:2881–2887.
   PubMed Web of Science ®Google Scholar
• Marcinkiewicz J, Chain BM, Olszowska E, Enhancement of immunogenic properties of ovalbumin as a result of its chlorination. Intl J Biochem 1991;23:1393–1395.
   Google Scholar
• Marcinkiewicz J, Olszowska E, Olszowski S, Zgliczynski J. Enhancement of trinitrophenyl-specific humoral response to TNP proteins as the result of carrier chlorination. Immunology 1992;76:385–388.
   Google Scholar
• Stark JM. Immunological adjuvance of metabolic origin: Oxidative stress, postulated impaired function of thiol proteases and immunogenicity. Scand J Immunol 1998;48:475–479.
   Google Scholar
• Callahan MK, Chaillot D, Jacquin C, Differential acquisition of antigenic peptides by Hsp70 and Hsc70 under oxidative conditions. J Biol Chem 2002;277:33604–33609.
   Google Scholar
• Reth M. Hydrogen peroxide as second messenger in lymphocyte activation. Nat Immunol 2002;3:1129–1134.
   PubMed Web of Science ®Google Scholar
• Tatla S, Woodhead V, Foreman JC, Chain BM. The role of reactive oxygen species in triggering proliferation and IL-2 secretion in T cells. Free Rad Biol Med 1999;26:14–24.
   PubMedGoogle Scholar
• Chiang CL, Ledermann JA, Egla A, Oxidation of ovarian epithelial cancer cells by hypochlorous acid enhances immunogenicity and stimulates T cells that recognize autologous primary tumor. Clin Cancer Res 2008;14:4898–4907.
   PubMed Web of Science ®Google Scholar
• Chiang C, Ledermann J, Rad AN, Katz D, Chain B. Hypochlorous acid enhances immunogenicity and uptake of allogeneic ovarian tumor cells by dendritic cells to cross-prime tumor-specific T cells. Cancer Immunol Immunother 2006;55:1384–1395.
   PubMed Web of Science ®Google Scholar
• Anderson MM, Hazen SL, Hsu FF, Heinecke JW. Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive alpha-hydroxy and alpha,beta-unsaturated aldehydes by phagocytes at sites of inflammation. J Clin Invest 1997;99:424–432.
   PubMed Web of Science ®Google Scholar
• Anderson MM, Requena JR, Crowley JR, The myeloperoxidase system of human phagocytes generates Nε-(carboxymethyl)lysine on proteins: A mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 1999;104:103–113.
   PubMed Web of Science ®Google Scholar
• Hazen SL, Hsu FF, Mueller DM, Human neutrophils employ chlorine gas as an oxidant during phagocytosis. J Clin Invest 1996;98:1283–1289.
   PubMed Web of Science ®Google Scholar
• Carrasco-Marín SE, Paz-Miguel J, López-Mato P, Oxidation of defined antigens allows protein unfolding and increases both proteolytic processing and exposes peptide epitopes which are recognized by specific T cells. Immunology 1998;95:314–321.
   PubMed Web of Science ®Google Scholar
• Feder ME, Hofmann GE. Heat-shock proteins, molecular chaperones, and the stress response: Evolutionary and ecological physiology. Annu Rev Physiol 1999;61:243–282.
   PubMed Web of Science ®Google Scholar
• Kakutani M, Masaki T, Sawamura T. A platelet–endothelium interaction mediated by lectin-like oxidized low-density lipoprotein receptor-1. Proc Natl Acad Sci U S A 2000;97:360–364.
   PubMedGoogle Scholar
• Oka K, Sawamura T, Kikuta K-I, Lectin-like oxidized low-density lipoprotein receptor 1 mediates phagocytosis of aged/apoptotic cells in endothelial cells. Proc Natl Acad Sci U S A 1998;95:9535–9540.
   Google Scholar
• Moriwaki H, Kume N, Sawamura T, Ligand specificity of LOX-1, a novel endothelial receptor for oxidized low density lipoprotein. Arterioscler Thromb Vasc Biol 1998;18:1541–1547.
   PubMed Web of Science ®Google Scholar
• Jono T, Miyazaki A, Nagai R, Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) serves as an endothelial receptor for advanced glycation end products (AGE). FEBS Lett 2002;511:170–174.
   PubMed Web of Science ®Google Scholar
• Shimaoka T, Kume N, Minami M, LOX-1 Supports adhesion of Gram-positive and Gram-negative bacteria. J Immunol 2001;166:5108–5114.
   PubMed Web of Science ®Google Scholar
• Marsche G, Levak-Frank S, Quehenberger O, Identification of the human analog of SR-BI and LOX-1 as receptors for hypochlorite-modified high-density lipoprotein on human umbilical venous endothelial cells. FASEB J 2001;15:1095–1097.
   Google Scholar
• Delneste Y, Magistrelli G, Gauchat J-F, Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity 2002;17:353–362.
   PubMed Web of Science ®Google Scholar
• Prokopowicz ZM, Arce F, Biedron R, Hypochlorous acid: A natural adjuvant that facilitates antigen processing, cross-priming, and the induction of adaptive immunity. J Immunol 2010;184:824–835.
   PubMed Web of Science ®Google Scholar
• Marsche G, Zimmermann R, Horiuchi S, Class B scavenger receptors CD36 and SR-BI are receptors for hypochlorite-modified low density lipoprotein. J Biol Chem 2003;278:47562–47570.
   Web of Science ®Google Scholar
• Ohgami N, Nagai R, Miyazaki A, scavenger receptor Class B Type I-mediated reverse cholesterol transport is inhibited by Advanced End products. J Biol Chem 2001;276:13348–13355.
   PubMed Web of Science ®Google Scholar
• Eager R, John N. GM-CSF gene-transduced tumor vaccines. Mol Ther 2005;12:18–27.
   PubMed Web of Science ®Google Scholar
• Simons J, Carducci M, Mikhak B, Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer. Clin Cancer Res 2006;12:3394–3401.
   PubMed Web of Science ®Google Scholar
• Small E, Sacks N, Nemunaitis J, Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 2007;13:3883–3891.
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Macarthur RB, O'Connor J, Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 1999;17:958–967.
   PubMed Web of Science ®Google Scholar
• Savarese DM, Halabi S, Hars V, Phase II Study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780. J Clin Oncol 2001;19:2509–2516.
   PubMed Web of Science ®Google Scholar
• Small E, Tchekmedyian N, Rini B, A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007;13:1810–1815.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Drake CG. Current status of immunological therapies for prostate cancer. Curr Opin Urol 2010;20:241–246.
   PubMed Web of Science ®Google Scholar
• Melcher A, Todryk S, Hardwick N, Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med 1998;4:581–587.
   PubMed Web of Science ®Google Scholar
• Arroyo PJ, Bash JA, Wallack MK. Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferon α in a murine hepatic metastasis model. Cancer Immunol Immunother 1990;31:305–311.
   PubMed Web of Science ®Google Scholar
• Sinkovics JG. Viral oncolysates as human tumor vaccines. Int Rev Immunol 1991;7259–7287.
   Google Scholar
• Berthier-Vergnes O, Portoukalian J, Lefthériotis E, Doré J-F. Induction of IgG antibodies directed to a Mr 31,000 melanoma antigen in patients immunized with Vaccinia Virus melanoma oncolysates. Cancer Res 1994;54:2433–2439.
   Google Scholar
• Marc KW, Muthukumaran S, Charles MB, Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 1998;187:69–79.
   Google Scholar
• Freedman R, Edwards C, Bowen J, Viral oncolysates in patients with advanced ovarian cancer. Gynecol Oncol 1988;29:337–347.
   PubMed Web of Science ®Google Scholar
• Ioannides C, Platsoucas C, Freedman R. Immunological effects of tumor vaccines: II. T cell responses directed against cellular antigens in the viral oncolysates. In Vivo 1990;4:17–24.
   PubMedGoogle Scholar
• Ioannides C, Platsoucas C, Patenia R, T-cell functions in ovarian cancer patients treated with viral oncolysates: I. Increased helper activity to immunoglobulins production. Anticancer Res 1990;10:645–653.
   PubMed Web of Science ®Google Scholar
• Schirrmacher V. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: Improvement of patient survival based on improved antitumor immune memory. Cancer Immunol Immunother 2005;54:587–598.
   PubMed Web of Science ®Google Scholar
• Ahlert T, Sauerbrei W, Bastert G, Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer [published erratum appears in J Clin Oncol 1997 Jul;15:2763]. J Clin Oncol 1997;15:1354–1366.
   PubMed Web of Science ®Google Scholar
• Coukos G, Makrigiannakis A, Kang EH, Molnar-Kimber oncolytic Herpes Simplex Virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer. Clin Cancer Res 2000;6:3342–3353.
   PubMed Web of Science ®Google Scholar
• Aubert M, O'Toole J, Blaho JA. Induction and prevention of apoptosis in human HEp-2 cells by Herpes Simplex Virus Type 1. J Virol 1999;73:10359–10370.
   PubMed Web of Science ®Google Scholar
• Galvan V, Roizman B. Herpes simplex virus 1 induces and blocks apoptosis at multiple steps during infection and protects cells from exogenous inducers in a cell-type-dependent manner. Proc Natl Acad Sci U S A 1998;95:3931–3936.
   PubMed Web of Science ®Google Scholar
• Miklos Z, Danis VA, Adams S, In vivo production of cytokines and β (C-C) chemokines in human recurrent Herpes Simplex lesions—do Herpes Simplex Virus-infected keratinocytes contribute to their production? J Infect Dis 1998;177:827–838.
   Google Scholar
• Benencia F, Coukos G. Biological therapy with oncolytic Herpesvirus. In: Coukos G, Berchuck A, Ozols R, eds. Ovarian Cancer. Vol. 622: New York: Springer; 2008. 221–233 pp.
   Google Scholar
• Benencia F, Courrèges M, Fraser N, Coukos G. Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation. Cancer Biol Ther 2008;7:1194–1205.
   PubMed Web of Science ®Google Scholar
• Jugovic P, Hill AM, Tomazin R, Inhibition of major histocompatibility complex Class I antigen presentation in pig and primate cells by Herpes Simplex Virus Type 1 and 2 ICP47. J Virol 1998;72:5076–5084.
   PubMed Web of Science ®Google Scholar
• Samaniego L, Wu N, DeLuca N. The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27. J Virol 1997;71:4614–4625.
   PubMed Web of Science ®Google Scholar
• Chiang CL-L, Benencia F, Coukos G. Whole tumor antigen vaccines. Semin Immunol 2010;22:132–143.
   PubMed Web of Science ®Google Scholar
• Berd D, Sato T, Maguire HC, Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 2004;22:403–415.
   PubMed Web of Science ®Google Scholar
• Berd D, Sato T, Cohn H, Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: Regression of pulmonary metastases. Int J Cancer 2001;94:531–539.
   PubMed Web of Science ®Google Scholar
• Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol 2007;19:3–10.
   PubMed Web of Science ®Google Scholar
• Hoebe K, Janssen E, Beutler B. The interface between innate and adaptive immunity. Nat Immunol 2004;5:971–974.
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4:499–511.
   PubMed Web of Science ®Google Scholar
• Malyala P, Chesko J, Ugozzoli M, The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles. J Pharm Sci 2008;97:1155–1164.
   PubMed Web of Science ®Google Scholar
• Vajdy M, Selby M, Medina-Selby A, Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. J Gen Virol 2006;87:2253–2262.
   PubMed Web of Science ®Google Scholar
• O'Hagan DT, Singh M, Kazzaz J, Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen. Vaccine 2002;20:3389–3398.
   PubMed Web of Science ®Google Scholar
• Wack A, Baudner BC, Hilbert AK, Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 2008;26:552–561.
   PubMed Web of Science ®Google Scholar
• Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: Concepts, achievements and perspectives. Expert Rev Vaccines 2007;6:723–739.
   PubMed Web of Science ®Google Scholar
• Brandau S, Suttmann H. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: A success story with room for improvement. Biomed Pharmacother 2007;61:299–305.
   PubMed Web of Science ®Google Scholar
• Uehori J, Matsumoto M, Tsuji S, Simultaneous blocking of human toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis Bacillus Calmette-Guerin Peptidoglycan. Infect Immun 2003;71:4238–4249.
   PubMed Web of Science ®Google Scholar
• Sondak VK, Sosman JA. Results of clinical trials with an allogeneic melanoma tumor cell lysate vaccine: Melacine®. Semin Cancer Biol 2003;13:409–415.
   PubMed Web of Science ®Google Scholar
• Alberts DS, Mason-Liddil N, O'Toole RV, Randomized phase III trial of chemoimmunotherapy in patients with previously untreated stage III, optimal disease ovarian cancer: A Southwest Oncology Group study. Gynecol Oncol 1989;32:16–21.
   Google Scholar
• Alberts DS, Moon TE, Stephens RA. Randomized study of chemoimmunotherapy for advanced ovarian carcinoma: A preliminary report of a Southwest Oncology Group study. Cancer Treat Rep 1979;63:325–331.
   PubMedGoogle Scholar
• Creasman WT, Gall S, Bundy BN, Second-look laparotomy in the patient with minimal residual stage III ovarian cancer (a Gynecologic Oncology Group study). Gynecol Oncol 1989;35:378–382.
   PubMed Web of Science ®Google Scholar
• Deiters U, Muhlradt PF. Mycoplasmal lipopeptide MALP-2 induces the chemoattractant proteins macrophage inflammatory protein 1 alpha (MIP-1alpha), monocyte chemoattractant protein 1, and MIP-2 and promotes leukocyte infiltration in mice. Infect Immun 1999;67:3390–3398.
   Google Scholar
• Kaufmann A, Muhlradt PF, Gemsa D, Sprenger H. Induction of cytokines and chemokines in human monocytes by mycoplasma fermentans-derived lipoprotein MALP-2. Infect Immun 1999;67:6303–6308.
   Google Scholar
• Schneider C, Schmidt T, Ziske C, Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model. Gut 2004;53:355–361.
   PubMed Web of Science ®Google Scholar
• Shingu K, Kruschinski C, Luhrmann A, Intratracheal macrophage-activating lipopeptide-2 reduces metastasis in the rat lung. Am J Respir Cell Mol Biol 2003;28:316–321.
   Google Scholar
• Schmidt J, Welsch T, Jager D, Intratumoural injection of the toll-like receptor-2/6 agonist ‘macrophage-activating lipopeptide-2’ in patients with pancreatic carcinoma: A phase I/II trial. Br J Cancer 2007;97:598–604.
   PubMed Web of Science ®Google Scholar
• Verdijk RM, Mutis T, Esendam B, Polyriboinosinic Polyribocytidylic Acid (Poly(I:C)) induces stable maturation of functionally active human dendritic cells. J Immunol 1999;163:57–61.
   PubMed Web of Science ®Google Scholar
• Jongbloed SL, Kassianos AJ, McDonald KJ, Human CD141+ (BDCA-3) +dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010;207:1247–1260.
   PubMed Web of Science ®Google Scholar
• Robinson R, DeVita V, Levy H, A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. J Natl Cancer Inst 1976;57:599–603.
   PubMedGoogle Scholar
• Thompson KA, Strayer DR, Salvato PD, Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection. Eur J Clin Microbiol Infect Dis 1996;15:580–587.
   PubMed Web of Science ®Google Scholar
• Strayer DR, Carter WA, Brodsky I, A controlled clinical trial with a specifically configured RNA drug, Poly(I). Poly(C12U), in chronic fatigue syndrome. Clin Infect Dis 1994;18:S88–S95.
   PubMed Web of Science ®Google Scholar
• Navabi H, Jasani B, Reece A, A clinical grade poly I:C-analogue (Ampligen®) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. Vaccine 2009;27:107–115.
   PubMed Web of Science ®Google Scholar
• Trumpfheller C, Caskey M, Nchinda G, The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci U S A 2008;105:2574–2579.
   PubMed Web of Science ®Google Scholar
• Cornell CJ, Smith K, Cornwell Gr, et al. Systemic effects of intravenous polyriboinosinic-polyribocytidylic acid in man. J Natl Cancer Inst 1976;57:1211–1216.
   PubMed Web of Science ®Google Scholar
• Freeman A, Al-Bussam N, O'Malley J, Pharmacologic effects of polyinosinic-polycytidylic acid in man. J Med Virol 1977;1:79–93.
   Google Scholar
• Sloat B, Cui Z. Nasal Immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic–polyribocytidylic acid induced strong mucosal and systemic immunities. Pharma Res 2006;23:1217–1226.
   Google Scholar
• Ichinohe T, Kawaguchi A, Tamura S-I, Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge. Microbes Infect 2007;9:1333–1340.
   PubMed Web of Science ®Google Scholar
• Kagan JC, Su T, Horng T, TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-[beta]. Nat Immunol 2008;9:361–368.
   PubMed Web of Science ®Google Scholar
• Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007;13:552–559.
   PubMed Web of Science ®Google Scholar
• Mata-Haro V, Cekic C, Martin M, The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007;316:1628–1632.
   PubMed Web of Science ®Google Scholar
• Baldridge JR, Crane RT. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods 1999;19:103–107.
   PubMed Web of Science ®Google Scholar
• Martin M, Michalek SM, Katz J. Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect Immun 2003;71:2498–2507.
   PubMed Web of Science ®Google Scholar
• ten Brinke A, van Schijndel G, Visser R, Monophosphoryl lipid A plus IFN-gamma maturation of dendritic cells induces antigen-specific CD8+ cytotoxic T cells with high cytolytic potential. Cancer Immunol Immunother 2010;59:1185–1195.
   Google Scholar
• Dubensky Jr., TW, Reed SG. Adjuvants for cancer vaccines. Semin Immunol 2010;22:155–161.
   PubMed Web of Science ®Google Scholar
• Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VFI. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 2008;13:859–875.
   PubMed Web of Science ®Google Scholar
• Meyer T, Stockfleth E. Clinical investigations of Toll-like receptor agonists. Expert Opin Investig Drugs 2008;17:1051–1065.
   PubMed Web of Science ®Google Scholar
• Schön MP, Schön M. TLR7 and TLR8 as targets in cancer therapy. Oncogene 2008;27:190–199.
   PubMed Web of Science ®Google Scholar
• Geller M, Cooley S, Argenta P, Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer Immunol Immunother 2010;59:1877–1884.
   PubMed Web of Science ®Google Scholar
• Dudek AZ, Yunis C, Harrison LI, First in human phase I trial of 852A, a novel systemic Toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin Cancer Res 2007;13:7119–7125.
   PubMed Web of Science ®Google Scholar
• Dummer R, Hauschild A, Becker JC, An exploratory study of systemic administration of the Toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin Cancer Res 2008;14:856–864.
   PubMed Web of Science ®Google Scholar
• Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007;117:1184–1194.
   PubMed Web of Science ®Google Scholar
• Ashino S, Wakita D, Zhang Y, CpG-ODN inhibits airway inflammation at effector phase through down-regulation of antigen-specific Th2-cell migration into lung. Int Immunol 2008;20:259–266.
   PubMed Web of Science ®Google Scholar
• De Cesare M, Sfondrini L, Campiglio M, Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN. J Immunother 2010;33:8–15.
   PubMedGoogle Scholar
• De Cesare M, Calcaterra C, Pratesi G, Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy. Clin Cancer Res 2008;14:5512–5518.
   Google Scholar
• Chuang C-M, Monie A, Wu A, Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer. Human Gene Ther 2009;20:303–313.
   PubMed Web of Science ®Google Scholar
• Goldstein MJ, Varghese B, Brody JD, A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors. Blood 2011;117:118–127.
   PubMed Web of Science ®Google Scholar
• Sfondrini L, Rossini A, Besusso D, Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer. J Immunol 2006;176:6624–6630.
   PubMed Web of Science ®Google Scholar
• Whitmore MM, DeVeer MJ, Edling A, Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res 2004;64:5850–5860.
   PubMed Web of Science ®Google Scholar
• Miles AP, McClellan HA, Rausch KM, Montanide® ISA 720 vaccines: Quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations. Vaccine 2005;23:2530–2539.
   PubMed Web of Science ®Google Scholar
• Lawrence GW, Saul A, Giddy AJ, Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720. Vaccine 1997;15:176–178.
   PubMed Web of Science ®Google Scholar
• Genton B, Al-Yaman F, Anders R, Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. Vaccine 2000;18:2504–2511.
   PubMed Web of Science ®Google Scholar
• Scalzo A, Elliott S, Cox J, Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720). J Virol 1995;69:1306–1309.
   PubMed Web of Science ®Google Scholar
• Hersey P, Menzies SW, Coventry B, Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma. Cancer Immunol Immunother 2005;54:208–218.
   PubMed Web of Science ®Google Scholar
• Hirunpetcharat C, Wipasa J, Sakkhachornphop S, CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP119) formulated in oil-based Montanides. Vaccine 2003;21:2923–2932.
   PubMed Web of Science ®Google Scholar
• Perlaza BL, Arevalo-Herrera M, Brahimi K, Immunogenicity of four Plasmodium falciparum preerythrocytic antigens in Aotus lemurinus monkeys. Infect Immun 1998;66:3423–3428.
   Google Scholar
• Oliveira GA, Wetzel K, Calvo-Calle JM, Safety and enhanced immunogenicity of a Hepatitis B Core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Infect Immun 2005;73:3587–3597.
   PubMed Web of Science ®Google Scholar
• Chianese-Bullock KA, Pressley J, Garbee C, MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and Montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J Immunol 2005;174:3080–3086.
   PubMed Web of Science ®Google Scholar
• Toledo H, Baly A, Castro O, A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers. Vaccine 2001;19:4328–4336.
   PubMed Web of Science ®Google Scholar
• Oka Y, Tsuboi A, Taguchi T, Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 2004;101:13885–13890.
   PubMed Web of Science ®Google Scholar
• Lawrence G, Cheng Q, Reed C, Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. Vaccine 2000;18:1925–1931.
   PubMed Web of Science ®Google Scholar
• Odunsi K, Qian F, Matsuzaki J, Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A 2007;104:12837–12842.
   PubMed Web of Science ®Google Scholar
• Diefenbach CSM, Gnjatic S, Sabbatini P, Safety and immunogenicity study of NY-ESO-1b peptide and Montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res 2008;14:2740–2748.
   Google Scholar
• Valmori D, Souleimanian NE, Tosello V, Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A 2007;104:8947–8952.
   PubMed Web of Science ®Google Scholar
• Leffers N, Lambeck AJA, Gooden MJM, Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer 2009;125:2104–2113.
   PubMed Web of Science ®Google Scholar
• Eisenbarth SC, Colegio OR, O'Connor W, Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008;453:1122–1126.
   PubMed Web of Science ®Google Scholar
• Hem SL, HogenEsch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev Vaccines 2007;6:685–698.
   PubMed Web of Science ®Google Scholar
• Morefield GL, Sokolovska A, Jiang D, Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 2005;23:1588–1595.
   PubMed Web of Science ®Google Scholar
• Goto N, Akama K. Histopathological studies of reactions in mice injected with aluminum-adsorbed tetanus toxoid. Microbiol Immunol 1982;26:1121–1132.
   PubMed Web of Science ®Google Scholar
• Goto N, Kato H, Maeyama J, Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties. Vaccine 1997;15:1364–1371.
   PubMed Web of Science ®Google Scholar
• Kool M, Soullié T, van Nimwegen M, Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008;205:869–882.
   PubMed Web of Science ®Google Scholar
• Wagner U, Köhler S, Reinartz S, Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: Immune responses and survival in palliative treatment. Clin Cancer Res 2001;7:1154–1162.
   PubMed Web of Science ®Google Scholar
• Podda A, Del Giudice G. MF59-adjuvanted vaccines: Increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2003;2:197–204.
   PubMedGoogle Scholar
• Kensil C, Patel U, Lennick M, Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol 1991;146:431–437.
   PubMed Web of Science ®Google Scholar
• Kensil C, Kammer R. QS-21: A water-soluble triterpene glycoside adjuvant. Expert Opin Investig Drugs 1998;7:1475–1482.
   PubMedGoogle Scholar
• Evans TG, McElrath MJ, Matthews T, QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans. Vaccine 2001;19:2080–2091.
   PubMed Web of Science ®Google Scholar
• Kashala O, Amador R, Valero MV, Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. Vaccine 2002;20:2263–2277.
   PubMed Web of Science ®Google Scholar
• Gahery-Segard H, Pialoux G, Figueiredo S, Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: Characterization of CD8+-T-Cell epitopes recognized. J Virol 2003 2003;77:11220–11231.
   Google Scholar
• Fogg CN, Americo JL, Lustig S, Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Vaccine 2007;25:2787–2799.
   PubMedGoogle Scholar
• Sabbatini PJ, Ragupathi G, Hood C, Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin Cancer Res 2007;13:4170–4177.
   PubMed Web of Science ®Google Scholar
• Gilewski T, Adluri S, Ragupathi G, Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 2000;6:1693–1701.
   PubMed Web of Science ®Google Scholar
• Ragupathi G, Livingston PO, Hood C, Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res 2003;9:5214–5220.
   PubMed Web of Science ®Google Scholar
• Sabbatini P, Spriggs D, Aghajanian C, Consolidation strategies in ovarian cancer: Observations for future clinical trials. Gynecol Oncol 2010;116:66–71.
   PubMedGoogle Scholar
• Sandmaier B, Oparin D, Holmberg L, Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. J Immunother 1999;22:54–66.
   PubMed Web of Science ®Google Scholar
• Miles D, Papazisis K. Rationale for the clinical development of STn-KLH (Theratope®) and anti–MUC-1 vaccines in breast cancer. Clin Breast Cancer 2003;3:S134–S138.
   PubMed Web of Science ®Google Scholar
• Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev 2002;188:147–154.
   PubMed Web of Science ®Google Scholar
• Rosenblatt J, Vasir B, Uhl L, Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood 2011 Jan 13;117:393–402.
   Google Scholar
• Weide B, Carralot J-P, Reese A, Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother 2008;31:180–188.
   PubMed Web of Science ®Google Scholar
• Dai S, Wei D, Wu Z, Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol Ther 2008;16:782–790.
   PubMed Web of Science ®Google Scholar
• Dranoff G. Tragets of protective tumor immunity. Cancer Vaccines, Annals NY Acad Sci 2009;1174:74–80.
   Google Scholar
• Borrello IM, Levitsky HI, Stock W, Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood 2009;114:1736–1745.
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Jahan T, Ross H, Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther 2006;13:555–562.
   PubMed Web of Science ®Google Scholar
• Tani K, Azuma M, Nakazaki Y, Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: Clinical and immunological findings. Mol Ther 2004;10:799–816.
   PubMed Web of Science ®Google Scholar
• Nemunaitis J. Granulocyte-macrophage colony-stimulating factor gene-transfected autologous tumor cell vaccine: Focus on non-small-cell lung cancer. Clin Lung Cancer 2003;5:148–157.
   PubMedGoogle Scholar
• Robinson HL, Montefiori DC, Villinger F, Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine. Virology 2006;352:285–294.
   PubMed Web of Science ®Google Scholar
• Dolcetti L, Peranzoni E, Ugel S, Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 2010;40:22–35.
   PubMed Web of Science ®Google Scholar
• Kurbacher C, Kurbacher J, Cramer E, Continuous low-dose GM-CSF as salvage therapy in refractory recurrent breast or female genital tract carcinoma. Oncology (Williston Park) 2005;19(4 Suppl):23–26.
   Google Scholar
• Roche MR, Rudd PJ, Krasner CN, Phase II trial of GM-CSF in women with asymptomatic recurrent Müllerian tumors. Gynecol Oncol 2010;116:168–172.
   Google Scholar
• de Vries EGE, Biesma B, Willemse PHB, A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma. Cancer Res 1991;51:116–122.
   PubMed Web of Science ®Google Scholar
• Schmeler KM, Vadhan-Raj S, Ramirez PT, A phase II study of GM-CSF and rIFN-[gamma]1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol 2009;113:210–215.
   PubMed Web of Science ®Google Scholar
• Elgueta R, Benson MJ, De Vries VC, Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 2009;229:152–172.
   PubMed Web of Science ®Google Scholar
• Graf D, Müller S, Korthäuer U, A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol 1995;25:1749–1754.
   PubMed Web of Science ®Google Scholar
• Mazzei GJ, Edgerton MD, Losberger C, Recombinant soluble trimeric CD40 ligand is biologically active. J Biol Chem 1995;270:7025–7028.
   PubMed Web of Science ®Google Scholar
• Cella M, Scheidegger D, Palmer-Lehmann K, Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996;184:747–752.
   PubMed Web of Science ®Google Scholar
• Lee BO, Moyron-Quiroz J, Rangel-Moreno J, CD40, but not CD154, expression on B cells is necessary for optimal primary B cell responses. J Immunol 2003;171:5707–5717.
   PubMed Web of Science ®Google Scholar
• Ghamande S, Hylander BL, Oflazoglu E, Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res 2001;61:7556–7562.
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Flaherty KT, Khalil M, Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007;25:876–883.
   PubMed Web of Science ®Google Scholar
• Advani R, Forero-Torres A, Furman RR, Phase I Study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's Lymphoma. J Clin Oncol 2009;27:4371–4377.
   PubMed Web of Science ®Google Scholar
• Johnson PW, Steven NM, Chowdhury F, A Cancer Research UK phase I study evaluating safety, tolerability, and biological effects of chimeric anti-CD40 monoclonal antibody (MAb), Chi Lob 7/4. J Clin Oncol 2010;28 (15s (suppl; abstr 2507)).
   Google Scholar
• Scarlett UK, Cubillos-Ruiz JR, Nesbeth YC, In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer–infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res 2009;69:7329–7337.
   PubMedGoogle Scholar
• Zeigler F, Bennett B, Jordan C, Cellular and molecular characterization of the role of the flk-2/flt-3 receptor tyrosine kinase in hematopoietic stem cells. Blood 1994;84:2422–2430.
   PubMed Web of Science ®Google Scholar
• Rasko J, Metcalf D, Rossner M, The flt3/flk-2 ligand: Receptor distribution and action on murine haemopoietic cell survival and proliferation. Leukemia 1995;12:2058–2066.
   Google Scholar
• Rosnet O, Schiff C, Pebusque M, Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood 1993;82:1110–1119.
   PubMed Web of Science ®Google Scholar
• Shibuya M, Yamaguchi S, Yamane A, Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990;5:519–524.
   PubMed Web of Science ®Google Scholar
• Hannum C, Culpepper J, Campbell D, Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 1994;368:643–648.
   PubMed Web of Science ®Google Scholar
• Lyman SD, James L, Bos TV, Molecular cloning of a ligand for the flt3 flk-2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cells. Cell 1993;75:1157–1167.
   PubMed Web of Science ®Google Scholar
• Lyman S, James L, Johnson L, Cloning of the human homologue of the murine flt3 ligand: A growth factor for early hematopoietic progenitor cells. Blood 1994;83:2795–2801.
   PubMed Web of Science ®Google Scholar
• McNeel DG, Knutson KL, Schiffman K, Pilot study of an HLA-A2 peptide vaccine using Flt3 ligand as a systemic vaccine adjuvant. J Clin Immunol 2003;23:62–72.
   Google Scholar
• Hunte B, Hudak S, Campbell D, flk2/flt3 ligand is a potent cofactor for the growth of primitive B cell progenitors. J Immunol 1996;156:489–496.
   Google Scholar
• Ray RJ, Paige CJ, Furlonger C, Flt3 ligand supports the differentiation of early B cell progenitors in the presence of interleukin-11 and interleukin-7. Eur J Immunol 1996;26:1504–1510.
   PubMed Web of Science ®Google Scholar
• Mackarehtschian K, Hardin JD, Moore KA, Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 1995;3:147–161.
   PubMed Web of Science ®Google Scholar
• Jacobsen S, Veiby O, Myklebust J, Ability of flt3 ligand to stimulate the in vitro growth of primitive murine hematopoietic progenitors is potently and directly inhibited by transforming growth factor-beta and tumor necrosis factor-alpha. Blood 1996;87:5016–5026.
   PubMed Web of Science ®Google Scholar
• Ohishi K, Katayama N, Itoh R, Accelerated cell-cycling of hematopoietic progenitors by the flt3 ligand that is modulated by transforming growth factor-beta. Blood 1996;87:1718–1727.
   PubMed Web of Science ®Google Scholar
• Freedman RS, Vadhan-Raj S, Butts C, Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas. Clin Cancer Res 2003;9:5228–5237.
   PubMed Web of Science ®Google Scholar
• Disis ML, Rinn K, Knutson KL, Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood 2002;99:2845–2850.
   PubMed Web of Science ®Google Scholar
• Matsumura N, Mandai M, Hamanishi J, Immunostimulatory effect of Fms-like tyrosine kinase 3 ligand on peripheral monocyte-derived dendritic cells and natural killer cells: Utilization for ovarian cancer treatment. Oncol Rep 2008;19:505–515.
   Google Scholar
• Silver DF, Hempling RE, Piver MS, Repasky EA. Flt-3 ligand inhibits growth of human ovarian tumors engrafted in severe combined immunodeficient mice. Gynecol Oncol 2000;77:377–382.
   Google Scholar
• Sudo Y, Shimazaki C, Ashihara E, Synergistic effect of FLT-3 ligand on the granulocyte colony-stimulating factor-induced mobilization of hematopoietic stem cells and progenitor cells into blood in mice. Blood 1997;89:3186–3191.
   PubMed Web of Science ®Google Scholar
• Geiger JD, Hutchinson RJ, Hohenkirk LF, Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001;61:8513–8519.
   PubMed Web of Science ®Google Scholar
• Stift A, Friedl J, Dubsky P, Dendritic cell-based vaccination in solid cancer. J Clin Oncol 2003;21:135–142.
   PubMed Web of Science ®Google Scholar
• Chang AE, Redman BG, Whitfield JR, A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 2002;8:1021–1032.
   PubMed Web of Science ®Google Scholar
• Janetzki S, Palla D, Rosenhauer V, Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer 2000;88:232–238.
   PubMed Web of Science ®Google Scholar
• Berd D. Autologous, hapten-modified vaccine as a treatment for human cancers. Vaccine 2001;19:2565–2570.
   PubMed Web of Science ®Google Scholar
• Chianese-Bullock KA, Irvin WPJ, Petroni GR, A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. I Immunothera 2008;31:420–430.
   PubMed Web of Science ®Google Scholar
• Morse MA, Alvarez Secord A, Blackwell KL, MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T cell responses against breast and ovarian cancer. Clin Cancer Res 2011 Feb 7. [Epub ahead of print] DOI:10.1158/1078–0432. CCR-10-2614.
   Google Scholar